15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Phase II trial of mirtazapine for cancer-related cachexia and anorexia.

      The American Journal of Hospice & Palliative Care
      Aged, Aged, 80 and over, Anorexia, drug therapy, etiology, Antidepressive Agents, Tricyclic, adverse effects, therapeutic use, Appetite, drug effects, Body Weight, Cachexia, Female, Humans, Male, Mianserin, analogs & derivatives, Middle Aged, Neoplasms, complications, Quality of Life

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA). The primary end point was the proportion of patients who gained > or =1 kg at week 4. Secondary end points were quality of life and appetite. From June 2006 to July 2007, 17 of 58 eligible patients were enrolled. On intention-to-treat analysis at week 4, 4 of 17 patients (24%) gained 1 kg or more, 1 patient maintained weight (gain of 400 g) and 2 patients lost weight (800 g and 1.2 kg); 24% and 6% improved appetite and health-related quality of life (HQOL), respectively. Mirtazapine is a promising agent for the treatment of CRCA.

          Related collections

          Author and article information

          Comments

          Comment on this article